Core computational partner across Chromatin3D, HaemMetabolome, PERICO, TranSYS, and EPHOR — all requiring integration of complex biological datasets.
LIFEGLIMMER GMBH
Berlin bioinformatics SME providing systems biology data analysis and multi-omics integration for health research and industrial biotech consortia.
Their core work
LifeGlimmer is a Berlin-based bioinformatics and systems biology SME that provides computational data analysis services to life science research consortia. They specialize in multi-omics data integration, systems analytics, and knowledge retrieval — essentially translating complex biological datasets into actionable insights. Their work spans from cancer metabolism and cell biology to occupational health and personalized medicine, always in the role of the computational partner that makes sense of large-scale biological data.
What they specialise in
TranSYS focused on translational systemics for personalized medicine; EPHOR applies omics-based approaches to occupational health biomarkers.
EmPowerPutida (re-factoring Pseudomonas putida) and IBISBA 1.0 (industrial biotech infrastructure) show applied biotech capabilities.
EPHOR (2020-2025) applies exposome research, cohort studies, and sensor data integration to occupational health — a newer direction.
PERICO (peroxisome interactions) and Chromatin3D (chromatin dynamics) involve computational modeling of subcellular processes.
How they've shifted over time
In their early H2020 period (2015-2018), LifeGlimmer focused on fundamental molecular biology — chromatin dynamics, cancer metabolism, and industrial biotechnology with Pseudomonas putida. From 2018 onward, their work shifted decisively toward translational applications: peroxisome systems biology, personalized medicine with sample-to-insight analytics, and occupational health exposomics. This trajectory shows a company moving from basic biological data analysis toward applied, patient- and worker-oriented health research with stronger emphasis on AI and multi-faceted knowledge retrieval.
LifeGlimmer is moving from fundamental research support toward applied health data analytics, with growing interest in AI-driven knowledge retrieval and real-world health outcome prediction.
How they like to work
LifeGlimmer has never coordinated an H2020 project — they consistently join as a specialist participant or third-party contributor, which is typical for computational SMEs that provide analytical services rather than driving research agendas. With 86 unique partners across 21 countries, they operate as a highly networked service provider embedded in diverse consortia rather than a hub with a fixed circle. This makes them an easy plug-in partner: experienced in large consortia, low coordination overhead, and comfortable adapting to different research domains.
Remarkably broad network for a small company: 86 unique consortium partners across 21 countries, reflecting their role as a versatile computational partner welcomed into diverse research teams across Europe and beyond.
What sets them apart
LifeGlimmer occupies a specific niche as a private bioinformatics SME that bridges computational systems biology with applied health research — a combination rare among German SMEs. Unlike university bioinformatics groups, they bring commercial agility and cross-domain flexibility, having worked across cancer, industrial biotech, cell biology, and occupational health. For consortium builders, they offer a reliable computational work package partner with proven track record in MSCA training networks and RIA projects alike.
Highlights from their portfolio
- EmPowerPutidaLargest single funding (EUR 581,750) — industrial biotechnology project for re-engineering Pseudomonas putida, showing LifeGlimmer's capacity beyond pure health research.
- TranSYSPersonalized medicine training network combining biomarker discovery, clinical trials design, and AI-driven sample-to-insight analytics — represents their most translational work.
- EPHORTheir most recent project (2020-2025), applying exposome research with sensors and omics to occupational health — signals their future direction.